Tag: Diabetes: Type II
GI Safety Profile Similar for Dulaglutide, Semaglutide, Tirzepatide
No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide
AHA: Low-Dose Aspirin Use Linked to Lower ASCVD Outcomes in Type 2 Diabetes
Any aspirin use linked to lower hazards of MI, ischemic stroke, with greater benefit in high-frequency use group
AHA: Optimal Heart Health Linked to Reduced MCI Risk in Type 2 Diabetes
Lower risk for MCI and dementia also seen with moderate, high cardiovascular health in those with high polygenic risk score
Type 2 Diabetes in Young Children Tied to Social, Environmental Factors
Childhood diabetes prevention programs should address broader issues of food access and quality, authors say
CHEST: Mortality Down With GLP-1 Receptor Agonist Use in T2D, Especially in Those With...
20 percent greater mortality benefit seen in obstructive sleep apnea population
New Diagnosis Code Added for Patients With Type 2 Diabetes in Remission
New ICD-10 diagnosis code is for patients with history of type 2 diabetes who bring blood sugar levels to a non-diabetic range below 6.5% for at least three months
ACS: 2020 to 2024 Saw Jump in Use of GLP-1 Receptor Agonists Before Metabolic,...
Even higher use seen in patients without type 2 diabetes
Continuous Glucose Monitors Not Accurate in People Without Diabetes
Authors say in those without diabetes, continuous glucose monitors are not a substitute for HbA1c
Weight-Loss Treatment Tied to Lower Risk for Obesity-Related Cancers
Findings seen for both medication and surgical procedures in people with obesity and type 2 diabetes
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
Findings seen for long-term outcomes among adult patients with diabetes and obesity












